Waldron Private Wealth LLC Increases Stock Position in Boston Scientific Co. (NYSE:BSX)

Waldron Private Wealth LLC lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 100.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,238 shares of the medical equipment provider’s stock after purchasing an additional 5,140 shares during the period. Waldron Private Wealth LLC’s holdings in Boston Scientific were worth $914,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Quarry LP bought a new position in shares of Boston Scientific in the second quarter valued at approximately $33,000. Truist Financial Corp increased its position in shares of Boston Scientific by 1.1% during the 2nd quarter. Truist Financial Corp now owns 214,594 shares of the medical equipment provider’s stock valued at $16,526,000 after purchasing an additional 2,254 shares during the last quarter. Sanctuary Advisors LLC purchased a new position in shares of Boston Scientific in the 2nd quarter worth about $5,349,000. Czech National Bank grew its position in Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after buying an additional 19,833 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in Boston Scientific by 68.6% during the third quarter. Handelsbanken Fonder AB now owns 2,371,407 shares of the medical equipment provider’s stock worth $198,724,000 after buying an additional 965,080 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on BSX. Sanford C. Bernstein boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Wells Fargo & Company upped their price objective on Boston Scientific from $98.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Truist Financial raised their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Stifel Nicolaus upped their price target on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, Mizuho lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. One analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Buy” and an average price target of $99.73.

Boston Scientific Stock Down 0.6 %

BSX opened at $102.40 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The business’s fifty day simple moving average is $93.47 and its 200 day simple moving average is $86.21. Boston Scientific Co. has a 52 week low of $62.63 and a 52 week high of $104.25. The stock has a market cap of $150.92 billion, a PE ratio of 84.63, a P/E/G ratio of 2.69 and a beta of 0.80.

Insider Activity

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now directly owns 39,398 shares in the company, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 29,989 shares of company stock worth $2,702,261. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.